Loss of Human Epidermal Receptor 2 Expression in Formalin-Fixed Paraffin-Embedded Breast Cancer Samples and the Rescuing Effect of Enhanced Antigen Retrieval and Signal Amplification

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Jan 23

PMID 38255647

Authors

Xiuli Ma

Lixin Zhou

Qi Wu

Ling Jia

Xinting Diao

Qiang Kang

Xiaozheng Huang

Yiqiang Liu

Taobo Hu

Mengping Long

Affiliations

Soon will be listed here.

Abstract

As an important therapeutic target in breast cancer, HER2 expression assessed by immunohistochemistry plays a critical role in breast cancer treatment. Recent advances in HER2 antibody-drug conjugate therapy have enabled patients with HER2-low expression breast cancer to benefit from the drugs. However, it is not known whether the HER2-low expression in breast cancer FFPE blocks would be lost as storage time increased. In this study, we aimed to assess the loss of HER2 antigenicity in stored FFPE blocks of breast cancer and the rescue effect of modifying the protocol of antigen staining. We selected archived HER2-low breast cancer FFPE blocks with stored time ranging from 1 year to over 15 years and re-detected the expression of HER2. Our study showed that HER2 antigenicity loss increased with storage time and could cause false negativity in HER2-low detection. Moreover, we showed that by either increasing the antigen retrieval time or applying the tyramide signal amplification (TSA) kit, the HER2 signal can be rescued and detected in about half of the cases with HER2-low loss without causing false positivity.

References

Shi S, Cote R, Taylor C . Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem. 1997; 45(3):327-43. DOI: 10.1177/002215549704500301. View

Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M . Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022; 29(1):1335-1344. PMC: 9090390. DOI: 10.1080/10717544.2022.2069883. View

Libson S, Lippman M . A review of clinical aspects of breast cancer. Int Rev Psychiatry. 2014; 26(1):4-15. DOI: 10.3109/09540261.2013.852971. View

Zhang H, Karakas C, Tyburski H, Turner B, Peng Y, Wang X . HER2-low breast cancers: Current insights and future directions. Semin Diagn Pathol. 2022; 39(5):305-312. DOI: 10.1053/j.semdp.2022.07.003. View

Li T, Mello-Thoms C, Brennan P . Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. Breast Cancer Res Treat. 2016; 159(3):395-406. DOI: 10.1007/s10549-016-3947-0. View

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E . Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022; 387(1):9-20. PMC: 10561652. DOI: 10.1056/NEJMoa2203690. View

Toda Y, Kono K, Abiru H, Kokuryo K, Endo M, Yaegashi H . Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method. Pathol Int. 1999; 49(5):479-83. DOI: 10.1046/j.1440-1827.1999.00875.x. View

Combs S, Han G, Mani N, Beruti S, Nerenberg M, Rimm D . Loss of antigenicity with tissue age in breast cancer. Lab Invest. 2015; 96(3):264-9. DOI: 10.1038/labinvest.2015.138. View

Ehinger A, Bendahl P, Ryden L, Ferno M, Alkner S . Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time. APMIS. 2018; 126(9):746-754. DOI: 10.1111/apm.12884. View

10.

Ponde N, Aftimos P, Piccart M . Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. Curr Treat Options Oncol. 2019; 20(5):37. DOI: 10.1007/s11864-019-0633-6. View

11.

Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J, Just M . Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8):1151-1161. DOI: 10.1016/S1470-2045(21)00301-6. View

12.

Fergenbaum J, Garcia-Closas M, Hewitt S, Lissowska J, Sakoda L, Sherman M . Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004; 13(4):667-72. View

13.

Kim K, Ylaya K, Perry C, Lee M, Kim J, Chung J . Quality Assessment of Proteins and RNA Following Storage in Archival Formalin-Fixed Paraffin-Embedded Human Breast Cancer Tissue Microarray Sections. Biopreserv Biobank. 2022; 21(5):493-503. PMC: 10623072. DOI: 10.1089/bio.2022.0090. View

14.

Zhang H, Katerji H, Turner B, Hicks D . HER2-Low Breast Cancers. Am J Clin Pathol. 2021; 157(3):328-336. DOI: 10.1093/ajcp/aqab117. View

15.

PUCHTLER H, Meloan S . On the chemistry of formaldehyde fixation and its effects on immunohistochemical reactions. Histochemistry. 1985; 82(3):201-4. DOI: 10.1007/BF00501395. View

16.

Olsen D, Ostergaard B, Bokmand S, Wamberg P, Jakobsen E, Brandslund I . HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med. 2007; 45(2):177-82. DOI: 10.1515/CCLM.2007.034. View

17.

Eiger D, Agostinetto E, Saude-Conde R, de Azambuja E . The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers (Basel). 2021; 13(5). PMC: 7957750. DOI: 10.3390/cancers13051015. View

18.

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

19.

Iqbal N, Iqbal N . Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014:852748. PMC: 4170925. DOI: 10.1155/2014/852748. View

20.

Shi S, Shi Y, Taylor C . Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem. 2011; 59(1):13-32. PMC: 3201121. DOI: 10.1369/jhc.2010.957191. View